Zydus Lifesciences' UK LiqMeds Facility Gets 4 USFDA Inspection Observations
Ahmedabad: The US Food and Drug Administration (USFDA) has concluded an inspection at the LiqMeds facility of Zydus Lifesciences Limited in the United Kingdom, with four observations.
The inspection was conducted from November 9 to November 13, 2026. Following the completion of the inspection, the USFDA issued four observations. Zydus Lifesciences stated that the company will closely work with the USFDA to address these observations expeditiously.
LiqMeds is part of Zydus Lifesciences’ international business operations and specialises in the development, manufacturing and supply of oral liquid pharmaceutical products for global markets. The group operates through its subsidiary, LM Manufacturing Limited (LMML), which has an oral liquid manufacturing facility at Weedon, Northampton, in the United Kingdom. The facility supplies products to markets in the UK and the United States.
Zydus Lifesciences acquired the UK-based LiqMeds Group in October 2023 through its wholly owned subsidiary, Zydus Pharmaceuticals UK Limited. The acquisition was aimed at strengthening the company’s capabilities in oral liquid formulations and expanding its presence in international pharmaceutical markets. The acquisition also provided Zydus with access to specialised manufacturing capabilities in liquid oral dosage forms.
Oral liquid formulations represent an important segment of pharmaceutical manufacturing, particularly for paediatric and geriatric patients and others who may experience difficulties swallowing solid dosage forms. The expansion of capabilities in this segment supports the development and supply of patient-friendly dosage forms across different markets.
Zydus Lifesciences Limited is an Ahmedabad-based, integrated global pharmaceutical and life sciences company with operations spanning pharmaceutical formulations, active pharmaceutical ingredients (APIs), vaccines, biosimilars, animal healthcare and consumer wellness products. The company has an international presence across several regulated and emerging markets and continues to focus on research, development, manufacturing and the expansion of its global healthcare portfolio.
Zydus has stated its commitment to working with the USFDA to address the four observations expeditiously.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.